BRPI0907532A2 - Anticorpos anti-c5ar humanizados - Google Patents

Anticorpos anti-c5ar humanizados

Info

Publication number
BRPI0907532A2
BRPI0907532A2 BRPI0907532-1A BRPI0907532A BRPI0907532A2 BR PI0907532 A2 BRPI0907532 A2 BR PI0907532A2 BR PI0907532 A BRPI0907532 A BR PI0907532A BR PI0907532 A2 BRPI0907532 A2 BR PI0907532A2
Authority
BR
Brazil
Prior art keywords
humanized anti
c5ar antibodies
c5ar
antibodies
humanized
Prior art date
Application number
BRPI0907532-1A
Other languages
English (en)
Inventor
Peter Whitfeld
David Zahra
Charles Reay Mackay
Original Assignee
G2 Inflammation Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by G2 Inflammation Pty Ltd filed Critical G2 Inflammation Pty Ltd
Publication of BRPI0907532A2 publication Critical patent/BRPI0907532A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
BRPI0907532-1A 2008-02-20 2009-02-19 Anticorpos anti-c5ar humanizados BRPI0907532A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US6653908P 2008-02-20 2008-02-20
PCT/AU2009/000184 WO2009103113A1 (en) 2008-02-20 2009-02-19 HUMANIZED ANTI-C5aR ANTIBODIES

Publications (1)

Publication Number Publication Date
BRPI0907532A2 true BRPI0907532A2 (pt) 2015-07-28

Family

ID=40984994

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0907532-1A BRPI0907532A2 (pt) 2008-02-20 2009-02-19 Anticorpos anti-c5ar humanizados

Country Status (14)

Country Link
US (3) US8268972B2 (pt)
EP (2) EP2254911B1 (pt)
JP (2) JP2011515073A (pt)
KR (1) KR20100117120A (pt)
CN (2) CN101970494B (pt)
AU (1) AU2009217224B2 (pt)
BR (1) BRPI0907532A2 (pt)
CA (1) CA2714296A1 (pt)
ES (1) ES2562627T3 (pt)
IL (1) IL207217A (pt)
MX (1) MX2010009190A (pt)
RU (1) RU2010138612A (pt)
WO (1) WO2009103113A1 (pt)
ZA (1) ZA201005348B (pt)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003062278A1 (en) 2002-01-25 2003-07-31 G2 Therapies Ltd MONOCLONAL ANTIBODIES AGAINST EXTRACELLULAR LOOPS OF C5aR
CN101506237B (zh) * 2006-08-22 2014-05-07 G2炎症私人有限公司 具有改进性能的抗-C5aR抗体
MX2010009190A (es) 2008-02-20 2010-09-10 G2 Inflammation Pty Ltd Anticuerpos anti-c5ar humanizados.
TW201022288A (en) 2008-06-30 2010-06-16 Novo Nordisk As Anti-human interleukin-20 antibodies
ES2620603T3 (es) * 2008-09-26 2017-06-29 Ucb Biopharma Sprl Productos biológicos
US8454956B2 (en) 2009-08-31 2013-06-04 National Cheng Kung University Methods for treating rheumatoid arthritis and osteoporosis with anti-IL-20 antibodies
RS61082B1 (sr) * 2010-02-26 2020-12-31 Novo Nordisk As Stabilno antitelo koje sadrži kompozicije
PT3345615T (pt) 2010-03-01 2020-01-17 Bayer Healthcare Llc Anticorpos monoclonais otimizados contra inibidor da via do fator tecidual (tfpi)
KR20130086144A (ko) 2010-05-28 2013-07-31 노보 노르디스크 에이/에스 항체 및 보존제를 포함하는 안정한 다중-투여 조성물
EP2468295A1 (en) 2010-12-21 2012-06-27 Affiris AG Vaccines based on peptides of the complement protein C5a
CN103596982B (zh) 2011-06-06 2016-11-02 诺沃—诺迪斯克有限公司 治疗性抗体
WO2014015133A1 (en) 2012-07-19 2014-01-23 National Cheng Kung University Treatment of osteoarthritis using il-20 antagonists
US8852588B2 (en) 2012-08-07 2014-10-07 National Cheng Kung University Treating allergic airway disorders using anti-IL-20 receptor antibodies
US8603470B1 (en) 2012-08-07 2013-12-10 National Cheng Kung University Use of IL-20 antagonists for treating liver diseases
US9592297B2 (en) 2012-08-31 2017-03-14 Bayer Healthcare Llc Antibody and protein formulations
US8613919B1 (en) 2012-08-31 2013-12-24 Bayer Healthcare, Llc High concentration antibody and protein formulations
GB201220242D0 (en) * 2012-11-09 2012-12-26 Fusion Antibodies Ltd Antibody
TWI635098B (zh) 2013-02-01 2018-09-11 再生元醫藥公司 含嵌合恆定區之抗體
WO2014180961A1 (en) * 2013-05-08 2014-11-13 Novo Nordisk A/S Use of c5ar antagonists
TWI701042B (zh) 2014-03-19 2020-08-11 美商再生元醫藥公司 用於腫瘤治療之方法及抗體組成物
MA51519A (fr) * 2014-05-05 2020-11-11 Regeneron Pharma Animaux c5 et c3 humanisés
EP3699198A1 (en) 2014-11-17 2020-08-26 Regeneron Pharmaceuticals, Inc. Methods for tumor treatment using cd3xcd20 bispecific antibody
WO2016096788A1 (en) * 2014-12-18 2016-06-23 F. Hoffmann-La Roche Ag Assay and method for determining cdc eliciting antibodies
EP3277725B1 (en) 2015-03-30 2020-11-25 Regeneron Pharmaceuticals, Inc. Heavy chain constant regions with reduced binding to fc gamma receptors
EP3292150B1 (en) 2015-05-04 2020-02-05 Cytomx Therapeutics Inc. Activatable anti-cd166 antibodies, and methods of use thereof
CN106957366B (zh) * 2016-01-12 2022-02-01 上海昀怡健康科技发展有限公司 一种C5aR抗体及其制备方法和应用
WO2018175833A1 (en) * 2017-03-23 2018-09-27 The Trustees Of The University Of Pennsylvania Anti-c5a antibodies and uses thereof
US11220544B2 (en) * 2017-07-14 2022-01-11 Cytomx Therapeutics, Inc. Anti-CD166 antibodies and uses thereof
KR102355755B1 (ko) * 2017-12-14 2022-02-08 코카 크롬 인더스트리 컴퍼니 리미티드 냉각롤 및 그것을 사용한 열가소성 수지 시트의 제조 방법
WO2020047389A1 (en) 2018-08-31 2020-03-05 Regeneron Pharmaceuticals, Inc. Dosing strategy that mitigates cytokine release syndrome for cd3/c20 bispecific antibodies
CN109439662B (zh) * 2018-11-15 2020-09-01 北京大学第三医院 用于C5aR1基因敲除的sgRNA、载体以及构建方法和检测方法
TW202140553A (zh) * 2020-01-13 2021-11-01 美商威特拉公司 C5ar1抗體分子及其用途
JP2024502863A (ja) * 2021-01-13 2024-01-23 ビステラ， インコーポレイテッド ヒト化補体５ａ受容体１抗体及びその使用方法

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL154598B (nl) * 1970-11-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking.
US3901654A (en) * 1971-06-21 1975-08-26 Biological Developments Receptor assays of biologically active compounds employing biologically specific receptors
US3817827A (en) 1972-03-30 1974-06-18 Scott Paper Co Soft absorbent fibrous webs containing elastomeric bonding material and formed by creping and embossing
US4098876A (en) 1976-10-26 1978-07-04 Corning Glass Works Reverse sandwich immunoassay
US4704362A (en) * 1977-11-08 1987-11-03 Genentech, Inc. Recombinant cloning vehicle microbial polypeptide expression
US4568649A (en) 1983-02-22 1986-02-04 Immunex Corporation Immediate ligand detection assay
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
EP0832981A1 (en) * 1987-02-17 1998-04-01 Pharming B.V. DNA sequences to target proteins to the mammary gland for efficient secretion
JPH02262599A (ja) 1989-01-03 1990-10-25 Merck & Co Inc ヒト多形核白血球からの精製Ｃ５ａレセプター
CA2062795A1 (en) 1989-06-29 1990-12-30 Michael W. Fanger Bispecific reagents for aids therapy
US5633076A (en) 1989-12-01 1997-05-27 Pharming Bv Method of producing a transgenic bovine or transgenic bovine embryo
US5284746A (en) * 1990-02-08 1994-02-08 Zymogenetics, Inc. Methods of producing hybrid G protein-coupled receptors
US5194594A (en) 1990-09-07 1993-03-16 Techniclone, Inc. Modified antibodies
US5173414A (en) 1990-10-30 1992-12-22 Applied Immune Sciences, Inc. Production of recombinant adeno-associated virus vectors
JPH06507398A (ja) 1991-05-14 1994-08-25 リプリジェン　コーポレーション Ｈｉｖ感染治療のための異種複合抗体
EP0672068A4 (en) 1992-09-25 1997-02-26 Commw Scient Ind Res Org TARGET MOLECULES BINDING POLYPEPTIDES.
DK0669836T3 (da) 1992-11-13 1996-10-14 Idec Pharma Corp Terapeutisk anvendelse af kimære og radioaktivt mærkede antistoffer og humant B-lymfocytbegrænset differentieringsantigen til behandling af B-cellelymfom
US5514555A (en) 1993-03-12 1996-05-07 Center For Blood Research, Inc. Assays and therapeutic methods based on lymphocyte chemoattractants
US5480974A (en) * 1993-06-18 1996-01-02 The Scripps Research Institute Antibodies to human C5a receptor
US5827690A (en) 1993-12-20 1998-10-27 Genzyme Transgenics Corporatiion Transgenic production of antibodies in milk
US5861272A (en) * 1995-06-02 1999-01-19 Human Genome Sciences, Inc. C5A receptor
JPH08109200A (ja) 1994-08-19 1996-04-30 Takeda Chem Ind Ltd 抗Ｃ５ａレセプター抗体、その製造法および用途
AUPO591797A0 (en) 1997-03-27 1997-04-24 Commonwealth Scientific And Industrial Research Organisation High avidity polyvalent and polyspecific reagents
WO1996039511A2 (en) 1995-06-05 1996-12-12 Incyte Pharmaceuticals, Inc. A C5a-LIKE SEVEN TRANSMEMBRANE RECEPTOR
ATE549918T1 (de) 1996-12-03 2012-04-15 Amgen Fremont Inc Menschliche antikörper, die ausdrücklich menschliches tnf alpha binden
CA2279344A1 (en) 1997-01-31 1998-08-06 Incyte Pharmaceuticals, Inc. Human c5a-like receptor
CA2288994C (en) 1997-04-30 2011-07-05 Enzon, Inc. Polyalkylene oxide-modified single chain polypeptides
US8007798B2 (en) 1997-11-21 2011-08-30 Genentech, Inc. Treatment of complement-associated disorders
WO2002038767A2 (en) 2000-11-07 2002-05-16 Genetics Institute, Llc. G protein-coupled receptor protein and nucleic acid molecules and uses therefor
WO2002061087A2 (en) 2000-12-19 2002-08-08 Lifespan Biosciences, Inc. Antigenic peptides, such as for g protein-coupled receptors (gpcrs), antibodies thereto, and systems for identifying such antigenic peptides
EP1409646B1 (en) 2000-12-19 2012-06-13 Altor BioScience Corporation Transgenic animals comprising a humanized immune system
US20030133939A1 (en) 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
TWI327597B (en) 2001-08-01 2010-07-21 Centocor Inc Anti-tnf antibodies, compositions, methods and uses
JP4603261B2 (ja) 2001-09-27 2010-12-22 メルク・シャープ・エンド・ドーム・コーポレイション ヒト化カルシトニン遺伝子関連ペプチド受容体をコードする単離ｄｎａ分子、関連する非ヒトトランスジェニック動物及びアッセイ方法
US7241444B2 (en) 2002-01-18 2007-07-10 Pierre Fabre Medicament Anti-IGF-IR antibodies and uses thereof
WO2003062278A1 (en) * 2002-01-25 2003-07-31 G2 Therapies Ltd MONOCLONAL ANTIBODIES AGAINST EXTRACELLULAR LOOPS OF C5aR
JP2006513702A (ja) 2002-09-09 2006-04-27 ヌラ インコーポレーティッド Ｇタンパク質共役受容体およびその使用
WO2004050683A2 (en) 2002-12-02 2004-06-17 Abgenix, Inc. Antibodies directed to tumor necrosis factor and uses thereof
US8101720B2 (en) 2004-10-21 2012-01-24 Xencor, Inc. Immunoglobulin insertions, deletions and substitutions
WO2005040219A1 (en) 2003-10-28 2005-05-06 Novo Nordisk A/S Laminin-5 gamma2-binding peptides, related compositions, and use thereof
EP1701611B1 (en) * 2003-12-24 2011-05-18 G2 Inflammation Pty Ltd Transgenic non-human mammal comprising a polynucleotide encoding human or humanized c5ar
BRPI0509264A (pt) * 2004-03-26 2007-09-04 Promics Pty Ltd tratamento de condições neurológicas que usa moduladores de receptor c5a de complemento
EP2567976B1 (en) 2005-03-23 2017-07-19 Genmab A/S Antibodies against CD38 for treatment of multiple myeloma
US7649951B2 (en) 2006-08-16 2010-01-19 Harris Corporation System and method for communicating data using symbol-based randomized orthogonal frequency division multiplexing (OFDM) with applied frequency domain spreading
CN101506237B (zh) 2006-08-22 2014-05-07 G2炎症私人有限公司 具有改进性能的抗-C5aR抗体
CN101501073A (zh) 2006-08-22 2009-08-05 G2英弗勒美欣私人有限公司 抗体制备方法
WO2008030564A2 (en) 2006-09-08 2008-03-13 Verenium Corporation Aglycosylated antibodies and methods of making and using those antibodies
AU2008314697B2 (en) 2007-10-22 2013-08-29 Merck Serono S.A. Single IFN-beta fused to a mutated lgG Fc fragment
MX2010009190A (es) 2008-02-20 2010-09-10 G2 Inflammation Pty Ltd Anticuerpos anti-c5ar humanizados.
WO2010000864A1 (en) 2008-07-04 2010-01-07 Novo Nordisk A/S Method for producing monoclonal antibodies
RS61082B1 (sr) 2010-02-26 2020-12-31 Novo Nordisk As Stabilno antitelo koje sadrži kompozicije
KR20130086144A (ko) 2010-05-28 2013-07-31 노보 노르디스크 에이/에스 항체 및 보존제를 포함하는 안정한 다중-투여 조성물

Also Published As

Publication number Publication date
US20120315275A1 (en) 2012-12-13
US8361468B2 (en) 2013-01-29
EP2254911A1 (en) 2010-12-01
CN101970494A (zh) 2011-02-09
EP2826791A3 (en) 2015-07-29
KR20100117120A (ko) 2010-11-02
US8268972B2 (en) 2012-09-18
IL207217A0 (en) 2010-12-30
US20110190477A1 (en) 2011-08-04
EP2826791A2 (en) 2015-01-21
EP2254911B1 (en) 2015-11-25
US20130129721A1 (en) 2013-05-23
AU2009217224B2 (en) 2014-09-11
CA2714296A1 (en) 2009-08-27
ZA201005348B (en) 2011-10-26
ES2562627T3 (es) 2016-03-07
RU2010138612A (ru) 2012-03-27
JP2011515073A (ja) 2011-05-19
AU2009217224A1 (en) 2009-08-27
IL207217A (en) 2015-03-31
JP2014193164A (ja) 2014-10-09
MX2010009190A (es) 2010-09-10
CN101970494B (zh) 2015-01-21
WO2009103113A1 (en) 2009-08-27
CN104193824A (zh) 2014-12-10
JP6034826B2 (ja) 2016-11-30
EP2254911A4 (en) 2011-10-19
US8808701B2 (en) 2014-08-19

Similar Documents

Publication Publication Date Title
CY2019004I1 (el) Τροποποιημενα αντισωματα αντι-ιl-23ρ19
BRPI0907532A2 (pt) Anticorpos anti-c5ar humanizados
SMT201700083B (it) Anticorpi monoclonali
CR20170001A (es) Anticuerpos anti factor d humanizados
BRPI0906877A2 (pt) Anticorpos anti-trkb aperfeiçoados
BRPI0923359A2 (pt) Anticorpos anti-igf
BRPI0907237A2 (pt) Anticorpo anti-cldn6
BRPI0819165A2 (pt) Anticorpos anti-vegf
DK2131860T3 (da) Anti-sclerostin-antistoffer
DK2344537T3 (da) Bispecifikke anti-vegf/anti-ang-2-antistoffer
DK2521736T3 (da) Humaniserede antistoffer
NO344963B1 (no) Humanisert antistoff
BRPI0821777A2 (pt) Anticorpos biespecíficos bivalentes
BRPI1011005A2 (pt) anticorpos anti-epcam
DK2459167T3 (da) SUBKUTAN ANTI-HER2-antistofformulering
EP2331579A4 (en) MONOCLONAL ANTIBODIES
BRPI1010297A2 (pt) anticorpos biespecíficos trivalentes.
BRPI0922800A2 (pt) anticorpos c-met
SG10201601279SA (en) Monoclonal Antibody STRO-4
EP2349331A4 (en) HUMANIZED ANTIBODIES TO IL-6
BRPI0917148A2 (pt) anticorpos anti-cd5
BRPI0821405A2 (pt) Anticorpos biespecíficos, bivalentes
BRPI0821375A2 (pt) Anticorpos biespecíficos, bivalentes
BRPI0916915A2 (pt) anticorpos anti-il-17a/f de reatividade cruzada e biespecíficos
IL204835A0 (en) Humanized antibody

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B11E Dismissal acc. art. 34 of ipl - requirements for examination incomplete
B11T Dismissal of application maintained [chapter 11.20 patent gazette]